EGFR and non-small cell lung carcinoma: In this economic evaluation, the clinical effectiveness and cost-effectiveness of 12 first-line treatments for advanced EGFR mutated NSCLC were evaluated based on the perspective of the UK NHS and the Chinese health care system.